Compare · ARGX vs ENTX
ARGX vs ENTX
Side-by-side comparison of argenx SE (ARGX) and Entera Bio Ltd. (ENTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ENTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 925.9x ENTX ($59.1M).
- Over the past year, ARGX is up 51.2% and ENTX is down 40.5% - ARGX leads by 91.8 points.
- ARGX has been more active in the news (5 items in the past 4 weeks vs 4 for ENTX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for ENTX).
- Company
- argenx SE
- Entera Bio Ltd.
- Price
- $882.63-1.03%
- $1.20+2.14%
- Market cap
- $54.76B
- $59.1M
- 1M return
- +12.11%
- -10.15%
- 1Y return
- +51.24%
- -40.55%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest ENTX
- SEC Form DEFA14A filed by Entera Bio Ltd.
- SEC Form DEF 14A filed by Entera Bio Ltd.
- Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
- SEC Form EFFECT filed by Entera Bio Ltd.
- SEC Form 424B3 filed by Entera Bio Ltd.
- SEC Form PRE 14A filed by Entera Bio Ltd.
- Chief Operating Officer Galitzer Hillel was granted 72,993 units of Ordinary Shares, increasing direct ownership by 81% to 163,566 units (SEC Form 4)
- Chief Financial Officer Yaacov-Garbeli Dana was granted 58,394 units of Ordinary Shares (SEC Form 4)
- Chief of R&D Burshtein Gregory was granted 87,591 units of Ordinary Shares, increasing direct ownership by 86% to 189,033 units (SEC Form 4)
- SEC Form S-3 filed by Entera Bio Ltd.